Latest Daily News

More Stories
June 6, 2016

An education session discussing biomarker identification in prostate cancer, potential future clinical applications for biomarkers, and the steps needed to make potential advances a reality. 

Read more
June 6, 2016

First-line checkpoint inhibitor atezolizumab could be new standard of care for cisplatin-ineligible patients with metastatic urothelial carcinoma. 

Read more

June 7, 2016

In women with platinum-sensitive relapsed ovarian cancer, maintenance therapy with olaparib does not provide a significant overall survival benefit, but long-term therapy is possible, according to an updated analysis of a randomized, double-blind phase II study.

Read more

June 7, 2016

Three abstracts detail data showing the role that evaluation of DNA damage repair genes have in tailoring treatment for metastatic prostate cancer and urothelial carcinoma.

Read more

June 7, 2016

Consideration of clinical trial data and anecdotal patient information can help oncologists weigh available treatment options to either help delay disease progression or avoid hormone therapy for patients with oligometastatic prostate cancer. 

Read more
June 5, 2016

In women with platinum-resistant or platinum-refractory recurrent ovarian cancer, health-related quality of life appears to predict early cessation of chemotherapy and shorter overall survival, and is more sensitive than ECOG performance status, based on an international prospective cohort study.

Read more

May 26, 2016

Drs. Christodouleas, Jason Efstathiou, and Libni Eapen discuss the recent advances in adjuvant radiation for the treatment of locally advanced bladder cancer and NRG Oncology’s NRG-GU001 clinical trial.

Read more

May 26, 2016

Drs. Rana R. McKay and Toni K. Choueiri discuss the ongoing studies exploring novel agents and combinations that will likely inform the future treatment landscape of patients with mRCC.

Read more

May 26, 2016

Dr. Timothy Gilligan discusses the prognosis and preferred treatment of adenocarcinoma of the urinary bladder. 

Read more

May 26, 2016

STAMPEDE uses a multi-arm, multi-stage platform design to answer many questions in a single trial, which saves time and money and makes the trial more efficient and effective than standard trials.

Read more

May 26, 2016

Dr. Rahul Aggarwal discusses the treatment options for patients with neuroendocrine prostate cancer presenting with systemic disease.

Read more

May 26, 2016

ASCO issued an endorsement for the European Association of Urology’s guideline on muscle-invasive and metastatic bladder cancer, including recommendations on multidisciplinary care, chemo- and radiotherapy, and other management issues.

Read more
May 29, 2015

Dr. George J. Bosl will receive the ASCO Distinguished Achievement Award for his pioneering work in research and patient care dealing with the management of testicular cancer and other genitourinary cancers.

Read more
May 30, 2015

 Ovarian function suppression has the potential to affect fertility, however providers should be aware of the role of adjuvant therapy and other interventions in helping patients maintain bone density and reduce fracture risk.

Read more
May 31, 2015

ASCO published guidelines and endorsements addressing myriad aspects of prostate cancer care, including radiotherapy in men after prostatectomy, hormone therapy and chemotherapy, and survivorship care.

Read more

May 31, 2015

Learn more about the inaugural year of the Maintenance of Certification (MOC) Self-Assessment Activity at the 2015 Genitourinary Cancer Symposium through an interview with participant Dr. Elizabeth Guancial.

Read more
May 30, 2015

Arguments for treating men with castration-resistant prostate cancer early or late were provided based on data from CHAARTED and GETUG-AFU 15. In addition, the use and sequencing of Ra 223 were also provided based on analyses from ALSYMPCA and datasets from clinical practice.

Read more
May 31, 2015

One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early stage breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of a randomized phase III trial.

Read more
June 7, 2015

Treatment with the Wee1 inhibitor AZD1775 plus carboplatin showed encouraging antitumor activity in patients with p53-mutated ovarian cancer that is refractory or resistant to standard first-line therapy.

Read more
May 31, 2015

The randomized phase III TOAD trial investigated whether immediate intervention with androgen deprivation therapy would improve overall survival compared with delayed androgen deprivation therapy in patients with prostate cancer.

Read more